玻璃体腔注射曲安奈德和阿霉素防治外伤性增生性玻璃体视网膜病变的实验研究被引量：1

下载PDF

导出

摘要目的:观察玻璃体腔注射曲安奈德和阿霉素治疗外伤性增生性玻璃体视网膜病变(proliferative vitreoretinopathy,PVR)的效果。方法:建立外伤性PVR动物模型。随机分为生理盐水组、曲安奈德组、阿霉素组、联合用药组。直接眼底镜观察PVR程度情况;酶联免疫吸附法(enzyme-liked immunosorbent assay,ELISA)测定玻璃体腔表皮生长因子(epidermal growth factor,EGF)、基质金属蛋白酶9(matrix metalloproteinase-9,MMP-9)浓度。结果:联合用药组PVR程度、玻璃体腔EGF、MMP-9浓度低于生理盐水组。结论:玻璃体腔注射曲安奈德和阿霉素可降低PVR形成程度,下调玻璃体腔EGF、MMP-9浓度。

作者招志毅彭燕一

机构地区桂林医学院附属医院眼科

出处《实用医学杂志》 CAS 北大核心 2010年第4期578-580,共3页 The Journal of Practical Medicine

基金广西科学自然基金资助项目(编号:桂科自0640191)

关键词玻璃体视网膜病增生性曲安奈德阿霉素治疗

分类号 R779.1 [医药卫生—眼科]

引文网络
相关文献

参考文献13

1Cheema R A,Peyman G A,Fang T,et al.Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy[J].Ophthalmic Surg Lasers Imaging,2007,38(5):365-370. 被引量：1
2Enaida H,Hata Y.Possible benefits of triamcinolone-assisted pars plana vitretomy for retinal diseases[J].Retina,2003,23(6):764-770. 被引量：1
3荣翱,李锦文.阿霉素联合地塞米松玻璃体内注射的临床应用[J].中华医学杂志,2002,82(8):546-548. 被引量：7
4Kuo H K,Wu P C,Yang P M,et al.Effects of topoisomerase Ⅱ inhibitors on retinal pigment epithelium and experimental proliferative vitreoretinopathy[J].J Ocul Pharmacol Ther,2007,23(1):14-20. 被引量：1
5Fasternberg D M,Diddie K R,Sorgente N,et al.A comparisonof different cellular inocula in an experimental modelof massive periretinal proliferation[J].Am J Ophthalmol,1982,93(5):559-572. 被引量：1
6Sheridan C M,OcclestonN L,Hiscott P,et al.Matrixmetalloprot einases:a role in the contraction of vitreo-retinal scar tissue[J].Am J Pathol,2001,159(4):1555-1561. 被引量：1
7Abu El-Asrar A M,Dralands L,Veckeneer M,et al.Gelatinase B in proliferative vitreoretinal disorders[J].Am J Ophthalmol,1998,125(6):844-851. 被引量：1
8Abu El-Asrar A M,Van den Steen P E,Al-Amro S A,et al.Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders[J].Int Ophthalmol,2007,27(1):11-22. 被引量：1
9Symeonidis C,Diza E,Papakonstantinou E,et al.Expression of matrix metalloproteinases in the subretinal fluid correlates with the extent of rhegmatogenous retinal detachment[J J.Grasfes Arch Clin Exp Ophthalmol,2007,245(4):560-568. 被引量：1
10Kon C H,Occleston N L,Charteris D G,et al.A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy[J].Invest Ophthalm ol Vis Sci,1998,39(8):1524-1529. 被引量：1

二级参考文献11

1Murphy G, Cocklett MI, Ward RV, et al. Matrix metalloproteinase degradation of elastin,type IV collagen and proteoglycans[ J ]. Biochem J,1991,277:277 - 279 被引量：1
2The Retina Society Terminology Committee. The classification of retinal detachment wih proliferative vitretinipathy [ J ]. Ophthalmology, 1983,90:121 - 125 被引量：1
3Kleinner DE, Stetler-Stevenson WG. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem, 1994,218: 325 - 329 被引量：1
4Girolamo ND, Verma M J, McCluskey PJ, et al. Increased matrix metalloproteeinases in the aqueous humor of patients and experiment animals with uveitis[ J]. Curr Eye Res, 1996,15:106 - 108 被引量：1
5Opdenakkeer G, Masure S, Proost P. Cytokine mediated regulation of human leukocyte gelatinases and role in arthritis [ J ]. Lymphokine Cytokine Res, 1991,10:317 - 324 被引量：1
6Brown D, Hamdi H, Bahri S, et al. Characterization of an endogenous metalloproteinase in human vitreous[ J ]. Curr Eye Res, 1994,13:639 被引量：1
7Tarlton JF, Vickery C J, Leaper DJ, et al. Post surgical wound progression monitored by temporal changes in the expression of matrix metalloproteinases-9 [ J ]. Br J Dermatol, 1997, 137: 506 - 516 被引量：1
8Agren MS. Gelatinase activity during wound healing[ J]. Br J Dermatol,1994,131: 634 - 640 被引量：1
9Kon CH, Occleston NL, Charteris D,et al. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy[ J]. Invest Ophthalmol Vis Sci, 1998,39: 1524 - 1529 被引量：1
10荣翱李锦文.阿霉素眼内注射剂量的实验研究[J].中华眼科杂志,1997,33:55-55. 被引量：5